RedShiftBio to Speak at Next-Generation Protein Analysis and Detection Conference
3rd Annual Next-Generation Protein Analysis and Detection Conference
We are proud to be speaking at the Next-Generation Protein Analysis and Detection Conference (Dec 2-3, 2019) in Ghent Belgium. The event focuses on ‘tools and technologies’ for protein analysis, specifically the front end of innovation.
The AQS3pro at Next-Generation Protein Analysis and Detection
Our CCO, Jeff Zonderman, will be presenting on our novel IR technology for biotherapeutic analytical tool boxes: Microfluidic Modulation Spectroscopy. The talk will be at 15.05pm on day 1 of the conference, as part of Session 1: Biosensing and Molecular Diagnostics
The continued success of protein therapeutics is driving the need for increased automation and higher performance measurement techniques to probe the conformational stability of biologics during development and manufacture. Infrared spectroscopy is a powerful technique for characterizing the secondary structure of proteins, which has a strong absorbance signature in the amide I band from 1600-1700 wavenumbers. However, the infrared measurement of proteins in aqueous solution is challenging because of strong water absorbance in the Amide I spectral window. Traditional methods such as FTIR with limited optical lack the sensitivity to adequately characterize proteins in solution, and just as importantly cannot be automated for high volume and bioprocessing applications.
A new technology, Microfluidic Modulation Spectroscopy (MMS), utilizes a tunable mid-infrared quantum cascade laser to generate a high power optical beam and focuses it through a microfluidic flow cell to capture infrared absorption spectra in the Amide I band. The high spectral power enables the use of longer pathlength cells (e.g. 23 um) to increase the measurement signal. The microfluid cell enables rapid real-time referencing of the sample under test which increases sensitivity and measurable protein concentration by over an order of magnitude compared to the prior state of the art.
The talk will present the results from a number of companies that clearly show the significance of the MMS technology in the development and manufacture of protein therapeutics. The results will include measurements of protein concentration, chemical stability, similarity, aggregation sensitivity relative to orthogonal l techniques such as SEC and mass spec. Also included will be a discussion of how MMS technology can improve workflow efficiency and eliminate buffer interference and other issues that can reduce measurement reliability and protein comparability.
We look forward to seeing you there!